Radiopharm Theranostics Limited (AU:RAD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Radiopharm Theranostics has received ethics approval in Australia to initiate a Phase 1 clinical trial of their innovative cancer treatment, 177Lu-RAD202, targeting HER2-positive metastatic solid tumors. This trial aims to explore the safety and clinical activity of the treatment, offering a potential new strategy for patients resistant to current therapies. The study underscores Radiopharm’s commitment to addressing unmet medical needs in oncology.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.